STOP-HAE: A Phase 3 Study of ADX-324 in HAE
STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
ADARx Pharmaceuticals, Inc.
90 participants
Aug 28, 2025
INTERVENTIONAL
Conditions
Summary
This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
siRNA duplex oligonucleotide
saline
Locations(51)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06960213